logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Tularik Limited


USPTO Granted Patents = 126

% Expired Patents = 19.0


Forward Citations = 1,482

Loading Chart...
Loading Chart...

119 inventors (with patents filed for the assignee):

goldMedal David V Goeddel (17 out of 92 patents)

silverMedal Mike Rothe (15 out of 44 patents)

bronzeMedal Bei Shan (14 out of 37 patents)

4.  Jin-Long Chen (14 out of 20 patents)

5.  Zhaodan Cao (13 out of 15 patents)

6.  Julio Cesar Medina (13 out of 73 patents)

7.  John A Flygare (11 out of 55 patents)

8.  Juan Carlos Jaen (10 out of 42 patents)

9.  Jonathan B Houze (10 out of 56 patents)

10.  Bohdan Waszkowycz (8 out of 9 patents)

11.  M Catherine Amaral (8 out of 10 patents)

12.  David Louis Clark (8 out of 14 patents)

13.  Terry J Rosen (7 out of 31 patents)

14.  Ning Zhang (6 out of 6 patents)

15.  Jay Patrick Powers (5 out of 126 patents)


Core Competencies:
Serine Protease Inhibitors
Pentafluorobenzenesulfonamides
High-Throughput Screening
Biaryl Compounds
IRAK-4
CXCR3 Antagonists
Antibacterial Agents
FXR Modulators
PPAR Modulators
Cholesterol Lowering Agents
Polycyclic Compounds
Nuclear Hormone Receptors

126 patents:

1. 7928137 - Meta-benzamidine derivatives as serine protease inhibitors (2011-04-19),
2. 7381734 - Serine protease inhibitors (2008-06-03),
3. 7220781 - Meta-benzamidine derivatives as serine protease inhibitors (2007-05-22),
4. 7157585 - Serine protease inhibitors (2007-01-02),
5. 7074934 - Serine protease inhibitors (2006-07-11),
6. 7067516 - Serine protease inhibitors (2006-06-27),
7. 6962929 - Pentafluorobenzenesulfonamides and analogs (2005-11-08),
8. 6916957 - Serine protease inhibitors (2005-07-12),
9. 6869975 - Linked biaryl compounds (2005-03-22),
10. 6822001 - Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents (2004-11-23),
11. 6818419 - IRAK-4: compositions and methods of use (2004-11-16),
12. 6809104 - Fused heterocyclic compounds (2004-10-26),
13. 6794379 - CXCR3 antagonists (2004-09-21),
14. 6780858 - Antibacterial agents (2004-08-24),
15. 6777446 - FXR modulators (2004-08-17),
Company Overview
Tularik Limited, based in South San Francisco, specializes in the development of innovative therapeutic solutions, focusing on serine protease inhibitors. The company is engaged in advanced research and technology, particularly in areas such as high-throughput screening and the synthesis of biaryl compounds. Tularik's expertise extends to the discovery of novel agents targeting IRAK-4 and CXCR3, as well as the development of antibacterial agents and FXR modulators, contributing to the advancement of healthcare solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

126 Patents

#12 in South San Francisco, CA

#698 in California

#3,085 in US

#6,370 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Tularik Limited

Forward Citations = 1,482

119 inventors:

goldMedal David V Goeddel (17 out of 92 patents)

silverMedal Mike Rothe (15 out of 44 patents)

bronzeMedal Bei Shan (14 out of 37 patents)

4.  Jin-Long Chen (14 out of 20 patents)

5.  Zhaodan Cao (13 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tularik Limited. Retrieved from https://idiyas.com/company/tularik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…